CARDIFF ONCOLOGY INC (CRDF:NASDAQ)
$1.02 0.022 (2.2044%)
Analysed CARDIFF ONCOLOGY INC (CRDF:NASDAQ) News Sources
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
21-05-2026
yahoo.com
CRDF: First Quarter 2026 Results
22-05-2026
yahoo.com
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
01-06-2026
yahoo.com
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
02-06-2026
yahoo.com
CRDF: Phase II Update; Survival Advantage Extended
22-06-2026
yahoo.com
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?
30-06-2026
yahoo.com
Cardiff Oncology Announces $10 Million Registered Direct Offering
15-07-2026
yahoo.com
Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital
15-07-2026
advfn.com
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
11-08-2026
yahoo.com
CRDF: Second Quarter Earnings
17-08-2026
yahoo.com
What is the current price of CARDIFF ONCOLOGY INC (CRDF:NASDAQ)?
The current price of CARDIFF ONCOLOGY INC (CRDF:NASDAQ) is $1.02.
CARDIFF ONCOLOGY INC (CRDF:NASDAQ) absolute price change since previous trading day?
The absolute price change of CARDIFF ONCOLOGY INC (CRDF:NASDAQ) since the previous trading day is $0.022.
CARDIFF ONCOLOGY INC (CRDF:NASDAQ) percentage price change since previous trading day?
The percentage price change of CARDIFF ONCOLOGY INC (CRDF:NASDAQ) since the previous trading day is 2.2044%.
What is the most recent average sentiment score for CARDIFF ONCOLOGY INC (CRDF:NASDAQ)?
The most recent average sentiment score for CARDIFF ONCOLOGY INC (CRDF:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for CARDIFF ONCOLOGY INC (CRDF:NASDAQ)?
The most recent sentiment for CARDIFF ONCOLOGY INC (CRDF:NASDAQ) is .
SEC-8K** Filing Available For CARDIFF ONCOLOGY INC (CRDF:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.